GNI Of Japan Submits Pirfenidone NDA With Shanghai FDA
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based GNI Dec. 21 announced it submitted an NDA application for pirfenidone to Shanghai FDA through its subsidiary Shanghai Genomics